Lu in vitro and in vivo using a tumour-targeted DOTA-folate conjugate (cm09).
− av =134 keV) due to similar physical decay characteristics but additional conversion and Auger electrons that may enhance the therapeutic efficacy. The goal of this study was to compare 161 Tb and 177 Lu in vitro and in vivo using a tumour-targeted DOTA-folate conjugate (cm09).
Methods

161
Tb-cm09 and 177 Lu-cm09 were tested in vitro on folate receptor (FR)-positive KB and IGROV-1 cancer cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay. In vivo 161 Tb-cm09 and 177 Lu-cm09 (10 MBq, 0.5 nmol) were investigated in two different tumour mouse models with regard to the biodistribution, the possibility for single photon emission computed tomography (SPECT) imaging and the antitumour efficacy. Potentially undesired side effects were monitored over 6 months by determination of plasma parameters and examination of kidney function with quantitative SPECT using 99m Tcdimercaptosuccinic acid (DMSA).
Results To obtain half-maximal inhibition of tumour cell viability a 4.5-fold (KB) and 1.7-fold (IGROV-1) lower radioactivity concentration was required for 161 Tb-cm09 (IC 50~0 .014 MBq/ ml and~2.53 MBq/ml) compared to 177 Lu-cm09 (IC 50 0.063 MBq/ml and~4.52 MBq/ml). SPECT imaging visualized tumours of mice with both radioconjugates. However, in therapy studies 161 Tb-cm09 reduced tumour growth more efficiently than 177 Lu-cm09. These findings were in line with the higher absorbed tumour dose for 161 Tb-cm09 (3.3 Gy/MBq) compared to 177 Lu-cm09 (2.4 Gy/MBq). None of the monitored parameters indicated signs of impaired kidney function over the whole time period of investigation after injection of the radiofolates. Conclusion Compared to 177 Lu-cm09 we demonstrated equal imaging features for 161 Tb-cm09 but an increased therapeutic efficacy for 161 Tb-cm09 in both tumour cell lines in vitro and in vivo. Further preclinical studies using other tumourtargeting radioconjugates are clearly necessary to draw final conclusions about the future clinical perspectives of
Introduction
The concept of peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues (e.g. DOTATATE and DOTATOC) proved its potential for the management of patients with inoperable or metastasized neuroendocrine tumours over many years [1, 2] . The first particle-emitting radioisotope used for PRRT was 90 Y, which decays with a half-life of 2.67 days by emission of β − -particles of a relatively high energy (Eβ − av =934 keV) [3] . In spite of the encouraging results obtained with PRRT, it has occasionally resulted in severe nephrotoxicity [4, 5] Tb belong to the group of lanthanides, the same (radio)chemistry may be applied and hence the formation of highly stable complexes of 177 Lu upon coordination by a DOTA chelator is also possible for 161 Tb [9] . Recently, we have implemented routine production of 161 Tb [9] at the Paul Scherrer Institute. The radiopharmaceutical utility of this and other Tb radioisotopes has been demonstrated in a recent proof-of-concept study [11] .
The aim of this study was to compare 161 Tb with 177 Lu and to evaluate potentially different features in terms of SPECT imaging and in vitro and in vivo antitumour efficacy. For this purpose we employed a recently developed DOTA-folate conjugate (cm09) which previously proved favourable in vitro and in vivo properties [13] . Due to the improved tissue distribution profile of 177 Lu-cm09 compared to conventional folate radioconjugates it could also be used for preclinical therapy experiments with tumour-bearing mice [11, 13] . Therefore, the folate conjugate (cm09) appeared to be an excellent tool to investigate 161 Tb and compare it with 177 Lu ( Fig. 1) . In vitro 161 Tb-cm09 and 177 Lu-cm09 were investigated with regard to their effects on the viability of folate receptor (FR)-positive cancer cells upon exposure to variable radioactivity concentrations. In vivo therapy studies were performed with 161 Tb-cm09 and 177 Lu-cm09 for direct comparison in established tumour mouse models. For this purpose we used KB (human cervical carcinoma) and IGROV-1 (human ovarian carcinoma) tumour xenografts. The two radiolanthanides 161 Tb and 177 Lu were also compared with regard to their potential for preclinical SPECT imaging, which we investigated by phantom studies and by in vivo scans in tumour-bearing mice.
Materials and methods
Radioisotopes
No-carrier-added (n.c.a.) 161 Tb was produced by irradiation of enriched 160 Gd targets for 3 weeks at the spallation-induced neutron source (SINQ) at PSI (Villigen-PSI, Switzerland) or by irradiation for 1 week at the high-flux nuclear reactor of ILL (Grenoble, France) [11] . Isolation and formulation of high concentrated 161 TbCl 3 in 0.05 M HCl (2-3 GBq/100 μl) was performed according to the procedure previously reported by Lehenberger et al. [9] . 177 LuCl 3 (in 0.04 M HCl) was obtained from Isotope Technologies Garching GmbH (ITG GmbH, Munich, Germany) at an activity concentration of 1 GBq/100 μl. The exact amount of radioactivity of these radionuclides was measured with a calibrated N-type highpurity germanium (HPGe) coaxial detector (EURISYS MESURES) and the Ortec InterWinner 5.0 software.
Radiofolate synthesis
Depending on the activity concentration of the radioisotopes, x μl of a 161 TbCl 3 or 177 LuCl 3 solution corresponding to Lu-cm09 at a specific activity of up to 30 MBq/nmol. The reaction solution was heated for 10 min at 95°C. After cooling down to room temperature Nadiethylenetriaminepentaacetic acid (Na-DTPA, 10 μl, 5 mM, pH 5) was added for complexation of potential traces of unreacted 161 Tb(III) and 177 Lu(III), respectively. Quality control was performed by HPLC using a C18 reversed phase column (XTerra MS C18, 5 μm, 15 cm × 4.6 cm, Waters). The mobile phase consisted of Milli-Q water with 0.1 % trifluoroacetic acid (A) and methanol (B) with a linear gradient from 5 % B to 80 % B over 25 min at a flow rate of 1 ml/min. In vitro cell viability assay Cell viability was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described by Mosmann [14] . KB cells and IGROV-1 cells (2,500 cells in 200 μl FFRPMI with supplements) were seeded in 96-well plates. After incubation overnight to allow adhesion of the cells, the supernatants were removed and the cells were incubated in 200 μl FFRPMI medium (without supplements) containing 161 Tb-cm09 and 177 Lu-cm09, respectively (0.0001-10 MBq/ml). Control assays were performed with cells incubated with FFRPMI medium without radioactivity. After 4 h incubation at 37°C, cells were washed once with 200 μl phosphate-buffered saline (PBS) followed by addition of 200 μl of FFRPMI medium (with supplements) to each well. Cells were grown over 4 days under standard cell culture conditions (37°C, 5 % CO 2 and high humidity), before addition of MTT reagent (5 mg/ml in PBS, 30 μl per well). The well plates were incubated for an additional 4 h allowing the formation of dark-violet formazan crystals. Upon replacement of the FFRPMI medium by dimethyl sulphoxide (DMSO, 200 μl per well) to dissolve the crystals, determination of the absorbance was carried out at 560 nm using a microplate reader (VICTOR X3, PerkinElmer). To quantify cell viability, the absorbance of the test samples was expressed as percentage of the absorbance of control cell samples which was set to 100 %. Sigmoid inhibition curves were determined and the radioactivity concentration (MBq/ml) which reduced cell viability to 50 % of untreated control cells was indicated as halfmaximal inhibitory concentration (IC 50 ) using GraphPad Prism (version 5).
In vivo studies
In vivo experiments were approved by the local veterinarian department and conducted in accordance with the Swiss law on animal protection. Four-to five-week-old female, athymic nude mice (CD-1 Foxn1/nu) were purchased from Charles River Laboratories (Sulzfeld, Germany). The animals were fed with a folate-deficient rodent diet (Harlan Laboratories) starting 5 days prior to tumour cell inoculation [15] .
SPECT/CT imaging studies SPECT/CT experiments were performed with a four-head multiplexing multi-pinhole camera (NanoSPECT/CT, Bioscan, Inc., Washington, DC, USA) using collimators of 4×9 holes with a diameter of 1.4 mm. The scans were acquired using Nucline software (version 1.02, Bioscan, Inc.). Mice were inoculated with KB cells (5×10 6 cells in 100 μl PBS) into the subcutis of each shoulder. Imaging studies were performed about 14 days after KB tumour cell inoculation. SPECT/CT scans were performed the day after intravenous injection of 161 Tb-cm09 (~30 MBq, 1 nmol) and 177 Lu-cm09 (~30 MBq, 1 nmol) with a time per view of 35 s resulting in a scan time of about 20-30 min. CT scans were performed with the integrated CT using a tube voltage of 55 kVp and an exposure time of 1,000 ms per view. After acquisition, SPECT data were reconstructed iteratively with HiSPECT software (version 1.4.3049, Scivis GmbH) using gamma energies of 47.7 keV (± 10 %) and 74.6 keV (± 10 %) for 161 Tb and gamma energies of 56.1 keV (± 10 %), 112.9 keV (± 10 %) and 208.4 keV (± 10 %) for 177 Lu. For each gamma line the energy peak had a full width of 20 %. The real-time CT reconstruction used a cone-beam filtered backprojection. SPECT and CT data were automatically coregistered as both modalities share the same axis of rotation. The fused data sets were analysed with the InVivoScope post-processing software (version 2.0, Bioscan, Inc.).
Blood clearance
Two groups of three non-tumour-bearing nude mice were intravenously injected with either 161 Tb-cm09 (20 MBq, 1 nmol) or 177 Lu-cm09 (20 MBq, 1 nmol). At different time points after injection (5 min, 15 min, 30 min, 1 h, 2 h, 6 h, 20 h, 48 h and 72 h) blood was taken from the tail vein or sublingual vein (3-40 μl) and measured in a gamma counter. The measured radioactivity per millilitre blood was calculated and converted into the percentage of the value measured at the first time point [5 min post-injection (p.i.)] which was set to 100 %.
Biodistribution studies
For post-mortem biodistribution studies mice were inoculated with IGROV-1 cells (6.5×10 6 cells in 100 μl PBS) into the subcutis of each shoulder. The experiments were performed in triplicate approximately 16 days after tumour cell inoculation. The radioconjugates were diluted with PBS to the desired specific activity (2-3 MBq, 0.5 nmol per mouse) for immediate administration via a lateral tail vein. The animals were sacrificed at specified time points between 1 h p.i. and 168 h p.i. and tissues and organs were collected, weighed and counted for radioactivity in a gamma counter. The results were listed as the percentage of the injected dose per gram of tissue weight (%ID/g), using reference counts from a defined volume of the original injectate that was counted at the same time.
To estimate the equivalent absorbed radiation dose for 161 Tbcm09 and 177 Lu-cm09 in tumour xenografts and in the kidneys, the following assumptions were made. First, the biodistribution data were considered as equal for 161 Tb-cm09 and 177 Lu-cm09 and second, the uptake in KB and IGROV-1 tumour xenografts was considered as the same (Supplementary Material).
In vivo therapy studies Mice were inoculated with KB cells (4.5×10 6 cells in 100 μl PBS) or IGROV-1 cells (7×10 6 cells in 100 μl PBS) under the skin of each shoulder 4 days before the start of therapy at day 0. Mice were weighed 3-4 times a week over a time period of about 7 weeks. Tumour volume was determined every other day using a digital caliper and calculated according to the equation
)] where L is the measurement of the longest axis and W is the measurement of the axis perpendicular to L in millimetres [16] . The relative tumour volume (RTV) was defined as [V x /V 0 ] where V x is the volume in cubic millimetres at a given time x and V 0 at day 0. The efficacy of the folate radioconjugate application was expressed as the percentage tumour growth inhibition (% TGI), calculated using the equation [100 − (T/C × 100)], where T is the mean RTVof the treated mice and C is the mean RTV in the control group at the time of euthanasia of the first mouse of the control group [17] . Tumour growth delay (TGD x ) was calculated as the time required for the tumour volume to increase x-fold over the initial volume at day 0. Tumour growth delay index (TGDI x ) was calculated as the TGD x ratio of treated over control mice [TGDI x =TGD x (T)/ TGD x (C)]. For the present studies we calculated the TGD as the time required to observe a fivefold (TGD 5 ) and tenfold (TGD 10 ) increase of the initial tumour volume allowing the determination of TGDI 5 and TGDI 10 .
Endpoint criteria were defined as body weight loss of >15 % of the initial body weight (at day 0), tumour volume >1,500 mm 3 (KB xenografts) or >1,000 mm 3 (IGROV-1 xenografts), ulceration or bleeding of the tumour xenograft or abnormal behaviour indicating pain or unease of the animal. Mice were removed from the study and euthanized upon reaching one of the predefined endpoint criteria. To calculate significance of the survival time or TGD, a t test (Microsoft Excel software) was used. All analyses were two-tailed and considered as type 3 (two sample unequal variance). A p value<0.05 was considered statistically significant. Lu-cm09 In a separate experiment three groups (A-C) of non-tumour-bearing nude mice were intravenously injected with either only PBS (group A, n =3), with 20 MBq Tbcm09 (group B, n =6) or 177 Lu-cm09 (group C, n =3) at day 0. Mice were weighed 3-4 times a week over a time period of 6 months. Plasma parameters including alkaline phosphatase (ALP) and blood urea nitrogen (BUN) were measured from all mice at days 29, 69, 127 and 147 after the start of therapy. Plasma samples were prepared by centrifugation of blood samples (150-200 μl per mouse) drawn from the sublingual vein of each mouse and collected in heparinized vials (Microvette, 200 ml, Sarstedt, Nümbrecht, Germany). For each parameter a plasma volume of 10 μl was required for measurement using a Fuji Dri-Chem 40000i analyser (Polymed Medical Center AG, Glattbrugg, Switzerland).
Results
Radiosynthesis of 161
Tb-cm09 and 177 
Lu-cm09
Radiolabelling of the folate conjugate (cm09) with 161 Tb or 177 Lu was performed under equal conditions in a solution of sodium acetate and hydrochloric acid at pH 4.5. The radiolabelling was accomplished within 10 min incubation at 95°C. HPLC-based quality control revealed equal retention times (R t =19.45 min) for 161 Tb-cm09 and 177 Lu-cm09. The radiochemical yield of 161 Tb-cm09 and 177 Lu-cm09 was always >98 % at a specific activity of up to 30 MBq/nmol.
Cell experiments
The viability of KB and IGROV-1 cancer cells was investigated by MTT assays upon exposure of these cells to increasing radioactivity concentrations of 161 Tb-cm09 and 177 Lu-cm09. Determination of the IC 50 values-which represent the radioactivity concentration needed to reduce cell viability to 50 % of untreated controls-using KB cells revealed a concentration of 0.014±0.013 MBq/ml for 161 Tbcm09 and 0.063±0.021 MBq/ml for 177 Lu-cm09 (Fig. 2a) . For IGROV-1 cells an IC 50 value of 2.53±0.47 MBq/ml was obtained for 161 Tb-cm09 and 4.52±0.98 MBq/ml for 177 Lucm09 (Fig. 2b) .
In vivo SPECT/CT imaging studies
In vivo SPECT/CTstudies were performed 24 h after injection of 161 Tb-cm09 and 177 Lu-cm09 in tumour-bearing mice (Fig. 3) . High accumulation of radioactivity was found in KB tumour xenografts located on each shoulder and in the kidneys which express the FR in the proximal tubules. Imaging quality was Tb-cm09 (Fig. 3a) and comparable to the quality obtained with a mouse which received 177 Lu-cm09 (Fig. 3b ).
Blood clearance
The results of the study which was performed to determine blood clearance values clearly showed equal clearance curves for 161 Tb-cm09 and 177 Lu-cm09 over the whole time of investigation (Fig. 4) Lu-cm09 in KB tumour-bearing mice have recently been reported by our group [11, 13] . Herein, additional tissue distribution data were obtained in IGROV-1 tumour-bearing mice after injection of Table S1 ). The uptake of Tb-cm09 (green) and 177 Lucm09 (red) shown as the blood activity in % of the initially measured radioactivity (5 min p.i. of the radioconjugates) in the blood which was set to 100 % Therapy studies
The time course of tumour growth in control mice with KB tumours (model 1) was slightly different than in mice bearing IGROV-1 tumours (model 2). While the size of all KB tumours increased uniformly over time, more variability in tumour size and faster tumour growth was observed for IGROV-1 tumour xenografts (Fig. 6a, b) . The first control mouse of model 1 had to be euthanized at day 26, whereas in model 2 the first control mouse was euthanized already at day 16, both because of oversized tumours. A clearly reduced tumour growth was found in both groups of mice which received radionuclide therapy, independent of the radioconjugate ( 161 Tb-cm09 versus 177 Lucm09) and the tumour mouse model (KB versus IGROV-1) (Fig. 6a, b) . Consistent in both tumour mouse models was a more pronounced antitumour effect in mice which received 161 Tb-cm09 (group B) than in mice which received 177 Lucm09 (group C). This observation was quantified by calculation of the TGI. In model 1 the TGI was 72 % for mice which received 161 Tb-cm09. This value was significantly (p <0.005) higher than the TGI of 46 % which was observed in mice treated with 177 Lu-cm09. Also, in model 2 the TGI of 90 % for the mice which received 161 Tb-cm09 was significantly (p <0.05) increased compared to the TGI of 83 % obtained in animals treated with 177 Lu-cm09 ( Table 2 ). The TGD indices TGDI 5 and TGDI 10 were increased for mice treated with 161 Tb-cm09 compared to mice treated with 177 Lu-cm09 in both models (1 and 2, Table 2 ).
The average survival time in KB tumour-bearing mice (model 1) was 31 days for control mice (group A), 54 days Tb-cm09 (group B) and 35 days for mice treated with 177 Lu-cm09 (group C). In mice with IGROV-1 tumour xenografts (model 2) the average survival time was 19 days for control mice (group A), 31 days for mice treated with 161 Tb-cm09 (group B) and 30 days for mice treated with 177 Lu-cm09 (group C) (Fig. 6c, d , Table 2 ).
Comparison of side-effects after therapy with 161 Tb-cm09 and 177 
Lu-cm09
The average value for the two plasma parameters ALP and BUN was in the same range for mice treated with 161 Tb-cm09 and 177 Lu-cm09 (groups A and B) and control mice (Table 3) . Only at day 127 did mice treated with 177 Lu-cm09 show an increased value of the ALP level relative to control mice of group A. However, at day 174 the values of the two groups of animals were again in the same range.
During the whole time of investigation plasma parameters such as aspartate aminotransferase, alanine aminotransferase, total bilirubin and albumin of treated mice did not differ significantly from those of control mice (Supplementary Material, Table S3 ). Moreover, the amount of viable, apoptotic and dead white blood cells were not significantly different among the two groups (B and C) of treated mice and among treated mice and untreated controls (Supplementary Material, Table S4 ). Investigations of renal uptake of 99m Tcdimercaptosuccinic acid (DMSA) using quantitative SPECT also did not reveal impairment of kidney function in animals which were treated with 161 Tb-cm09 and 177 Lu-cm09 (Supplementary Material).
Discussion
In this study 161 Tb and 177 Lu were compared in vitro and in vivo. Radiolabelling of the DOTA-folate conjugate cm09 was accessible at high specific activity with both radiolanthanides. SPECT phantom studies of 161 Tb and 177 Lu revealed an excellent imaging quality and a resolution which was comparable for both radionuclides (Supplementary Material, Fig. S1 ). The quality of the mouse images obtained from in vivo SPECT/CT studies confirmed equal suitability of 161 Tb and 177 Lu for preclinical imaging purposes. The lowenergy gamma rays of 161 Tb may be advantageous in view of a clinical application as they result in reduced radiation exposure of non-targeted tissue (e.g. bone marrow) [9, 18] . On the other hand low-energy gamma rays of 161 Tb may not be equally appropriate for imaging purposes in patients because of less efficient penetration through the tissue compared to the higher gamma energies of 177 Lu (Table 1) . Time-dependent cell uptake and internalization studies confirmed equal in vitro characteristics of Material Fig. S4 ). As Material Fig. S5) . In KB cells a 4.5-fold lower radioactivity concentration was required for 161 Tb-cm09 to reduce cell viability to 50 % of untreated controls than for 177 Lu-cm09. In the case of IGROV-1 cells a 1.8-fold lower radioactivity concentration was required for 161 Tb-cm09 to achieve the same effect as with 177 Lu-cm09. These in vitro findings were in line with the increased absorbed dose provided by Lu-cm09 demonstrated equal pharmacokinetic properties of these radioconjugates independent of whether they were radiolabelled with 161 Tb or 177 Lu. Also, both radioconjugates were shown to be stable in vivo, while formation of radioactive metabolites was not observed over at least 2 days after injection (Supplementary Material Fig. S6 ). The in vivo tissue distribution profile of Lu-cm09. These findings can be attributed to the fact that the absorbed dose in the tumour tissue was higher for 161 Tb-cm09 (3.3 Gy/MBq) than for 177 Lu-cm09 (2.4 Gy/MBq). IGROV-1 tumours grew faster than KB tumours but were more sensitive to radionuclide therapy as shown by the tumour growth curves in Fig. 6a, b . However, the difference of the inhibitory effects of 161 Tbcm09 and 177 Lu-cm09 on the tumour growth was more pronounced in KB tumours than in IGROV-1 tumours. The reason for this observation is not clear. Since the therapeutic efficacy of conversion and Auger electrons is clearly dependent on the accumulation of the radionuclide in the tumour cell [18] [19] [20] [21] , it is particularly the internalized fraction of the radioconjugate which would be crucial to benefit from the additional conversion and Auger electrons emitted by 161 Tb. Only marginal differences were observed among KB and IGROV-1 cells in terms of the internalized fraction of the radioconjugates in vitro (Supplementary Material,  Fig. S2 ). However, it could be that KB cells internalize the radioconjugates more efficiently in vivo which would explain why the difference among 161 Tb-cm09 and 177 Lu-cm09 in terms of TGD was greater in KB tumours than in IGROV-1 tumours.
The absorbed dose to the kidneys after application of 161 Tb-cm09 (4.5 Gy/MBq) or 177 Lu-cm09 (3.4 Gy/MBq) was relatively high. Hence, there was a potential risk of radio-nephrotoxicity. Therefore, an additional in vivo study was performed in which non-tumour-bearing mice received 20 MBq of 161 Tb-cm09 and 177 Lu-cm09, respectively. This high quantity of radioactivity was chosen because it was known to result in complete tumour regression [13] . Significant alterations of blood plasma parameters were not observed over the whole time period of 6 months. Moreover, SPECT experiments to quantify renal uptake of 99m Tc-DMSA were performed as a measure of kidney function. This method was previously reported by Forrer et al. who investigated kidney damage in rats after PRRT using 177 Lu-DOTATATE [22] . Our study revealed similar data for treated animals and untreated control animals independent of whether they received 161 Tbcm09 or 177 Lu-cm09 (Supplementary Material Fig. S7 , Fig. S8 and Fig. S9 ). With regard to undesired effects to the kidneys, further studies with a larger cohort of animals per group and variable amounts of injected radioactivity are currently ongoing in our laboratories.
Conclusion
Based on the in vivo studies presented in this work it can be concluded that 161 Tb-cm09 provides an enhanced antitumour effect compared to 177 Lu-cm09 in KB and IGROV-1 tumourbearing mice. Radiotoxic side effects were not observed for 161 Tb-cm09 and also not for 177 Lu-cm09 even at high quantities of injected radioactivity. These data indicate that 161 Tb could be a potent alternative to 177 Lu for targeted tumour therapy. Further preclinical studies using other tumourtargeting ligands labelled with 161 Tb and more detailed investigations about potential radiotoxic side effects are clearly necessary to draw final conclusions about the future clinical perspectives of 161 Tb.
